Evidence map›Paper›PMID 40103279›Full record

ArticleClinical and translational science2025

Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers.

Marliese Alexander, Chiao Xin Lim, Senthil Lingaratnam, Sarah Glewis, Joanne Wickens, Abbey Hird, Zi Yue Chen, Alistair Bozkurt, Amit Khot, David Routledge and 12 more

Abstract read
In one paragraph

Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Marliese AlexanderPharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-5782-7912
Chiao Xin LimPharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.ORCID 0000-0001-5543-8411
Senthil LingaratnamPharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-2678-5208
Sarah GlewisPharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-7764-5427
Joanne WickensPharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.ORCID 0000-0002-3722-4628
Abbey HirdPharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Zi Yue ChenPharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Alistair BozkurtPharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.ORCID 0009-0008-1519-6487
Amit KhotSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-9210-5373
David RoutledgeSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-9701-3216
Sam HarrisBendigo Cancer Centre, Bendigo Health, Bendigo, Victoria, Australia.
Craig UnderhillBorder Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre, Albury, New South Wales, Australia.ORCID 0000-0001-9335-2678
Ashley WhitechurchClinical Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.ORCID 0000-0003-1635-5562
Lydia LeongPharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Marcus PergoliniPharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Gail RowanPharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Monnette SamoPharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Chloe GeorgiouBendigo Cancer Centre, Bendigo Health, Bendigo, Victoria, Australia.
Peter SavasSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0001-5999-428X
Jenny DevineAlcohol and Other Drugs Committee, The Royal Australian College of General Practitioners, Melbourne, Victoria, Australia.
Alysia KepertConsumer Representative, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Safeera Y HussainyPharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-1418-8078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integration of clinical pharmacogenomics (PGx) within routine cancer care is limited despite frequent use of medicines impacted by PGx, evidence for the benefits of PGx, and the availability of international PGx clinical guidelines. Our study objective was to develop survey tools to assess PGx knowledge, attitudes, practices, perceptions, and education needs among (a) doctors, nurses, and pharmacists involved in cancer care (healthcare professionals, HCPs) and (b) adults who have received cancer treatment or their carers (consumers), with the view to informing implementation strategies for PGx in solid and hematologic cancers. Survey tools were developed in a three-phase (ph) mixed-methods approach. Content was informed by systematic literature review findings and framed by determinants of behavior as informed by the Theoretical Domains Framework (ph-1). Refinement occurred through four separate priority partnership meetings (ph-2). Meetings focused on clinical PGx practices within select cancer streams, and consumers' knowledge, attitudes, and preferences for PGx testing. Content/face validity and health literacy (Flesch Kincaid Grade Level) assessments informed final refinements (ph-3). Separate HCP and consumer survey tools were developed with six common sections: (1) introduction; (2) demographics; (3) experience; (4) knowledge, attitudes, practices and perceptions; (5) education; and (6) vignettes. Content and face validity were rated highly with acceptable health literacy assessments for questions within the consumer survey (median grade level 6; range 1-8). The developed survey tools will be used to generate evidence to inform local implementation strategies for PGx in cancer and promote broader integration of pharmacogenomics in routine clinical care.

Indexed as

Health PersonnelNeoplasmsPharmacogeneticsAdultAttitude of Health PersonnelFemaleHealth Knowledge, Attitudes, PracticeHealth LiteracyHumansMaleMiddle AgedPharmacogenomic TestingSurveys and Questionnairescancerconsumershealth professionalspharmacogenomicssurvey

Identifiers

PMID40103279
PMCPMC11919918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.